Selvita Group Receives GMP Certificate
Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, received a GMP certificate.
On 11 February 2014, after positive inspection conducted by the Main Pharmaceutical Inspectorate (the competent authority of Poland granting GMP certificates), BioCentrum, a part of Selvita Group received a certificate of compliance with the principles of Good Manufacturing Practice (GMP).
GMP certificate was granted based on positive results of GMP inspection conducted on 19–20 November 2013. The range of GMP certificate covers all services offered by the analytical laboratory, including physical and chemical testing in quality control of the pharmaceutical products. This certificate was issued for 3 years.
Positive results of the GMP inspection confirmed that Selvita complies with the standards and requirements of the GMP in its routine activities and all studies conducted in Selvita Group, are planned, performed, monitored, and reported in accordance with the international quality standards established by the pharmaceutical industry.
"GMP certification is an extremely important event in the Selvita’s development. Obtaining the GMP certificate proves that the quality of research is one of the strategic objectives of our company. The GMP and GLP certificates confirm that our laboratories are working according to the highest worldwide quality standards. Thanks to the GLP/GMP quality system our company is more recognizable in the world, and the results generated by our scientists are credible and accepted by the registration authorities in other countries," said Dr Miłosz Gruca, Director of Research and Development, Board Member of BioCentrum Sp. z o.o.
Selvita Group Analytical Laboratory joined the elite group of five Polish laboratories certified in both GMP and GLP.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...